Similar efforts to identify candidate biomarkers from phosphoproteomics analyses have recently been presented for dasatinib in nonsmall-cell lung cancer (39), for PI3K pathway inhibitors (47), and for the FLT3-inhibitor quizartinib in AML (23). The gene discussed is FLT3; the disease is lung cancer.